Schlieren, Zurich, Switzerland In 2006 was created Neurimmune Holding, which is appeared as Corporate Investor. The venture was found in Europe in Switzerland. The main department of described Corporate Investor is located in the Schlieren.
Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Therapeutics, Medical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Switzerland. Among the most popular portfolio startups of the fund, we may highlight NovaGo Therapeutics.
The current fund was established by Jan Grimm, Roger M Nitsch.
The high activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year.
The usual cause for the fund is to invest in rounds with 2 partakers. The meaningful sponsors for the fund in investment in the same round are TVM Capital Life Science, Pureos Bioventures.
| Fund Name | Location |
| Ambria Capital | NA - Puerto Rico, Puerto Rico, United States |
| GreenGage Capital | Illinois, United States, Wilmette |
| GW Asia Capital | - |
| Nanjing Youchuang Jiaye | China, Fujian, Zhangzhou |
| Pengpai | - |
| Pivot Ventures | - |
| Progression Fund | - |
| Sixt Rental Cars | Bavaria, Germany, Pullach Im Isartal |
| Solvay | Belgium, Brussels, Brussels Hoofdstedelijk Gewest |
| Stanford Angels of the United Kingdom | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
NovaGo Therapeutics | $10M | 04 Mar 2019 | Zurich, Switzerland | ||
AL-S Pharma | 08 Dec 2016 | Zurich, Switzerland |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
NovaGo Therapeutics | $10M | 04 Mar 2019 | Zurich, Switzerland | ||
AL-S Pharma | 08 Dec 2016 | Zurich, Switzerland |
